RecruitingPhase 4NCT06693726

Early Angiotensin II in the Emergency Department

ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study

Sponsor

Brett A Faine

Enrollment

20 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Conditions

Septic Shock

Summary

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria4

Age ≥18; and
Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
Can provide written informed consent (or legally authorized representative).

Exclusion Criteria8

Acute coronary syndrome;
Cardiogenic shock;
Patients with a history of mesenteric ischemia;
Patients with a history of having an aortic dissection or abdominal aortic aneurysm;
Patients with an expected lifespan of <12 hours;
Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);
Active administration of two vasoactive agents before enrollment; and
Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.